Familial Mediterranean Fever – clinical picture, diagnosis and treatment
Authors:
Tomáš Dallos; Denisa Ilenčíková; László Kovács
Authors‘ workplace:
II. detská klinika LF UK a DFNsP, Bratislava, Slovenská republika, prednosta prof. MUDr. László Kovács, DrSc., MPH
Published in:
Vnitř Lék 2014; 60(1): 30-37
Category:
Reviews
Overview
Familial mediterranean fever (FMF) is the most prevalent genetically determined autoinflammatory disease. FMF significantly decreases the quality of life and limits life expectancy due to the development of amyloidosis in affected individuals. Prevalence of FMF is highest in the south-eastern Mediterraneans. In other parts of the world, its occurance is often restricted to high-risk ethnic goups. In Central Europe, experience with FMF is scarse. As for Slovakia, we have reported the first cases of FMF in ethnic Slovaks only recently. Along with their complicated fates, this has lead us to compile a comprehensive overview of the clinical picture, diagnosis and treatment of this elusive disease. Hereby we hope to be able to promote the awareness about this disease and possibly aid the diagnosis in new patients.
Key words:
familial mediterranean fever – amyloidosis – colchicin – overview of the clinical picture
Sources
1. Dinarello CA. Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 2009; 360(23): 2467–2470.
2. Janeway TC, Mosenthal HO. Unusual paroxysmal syndrome, probably allied to recurrent vomiting, with a study of the nitrogen metabolism. Trans Assoc Am Physicians 1908; 23: 504–518.
3. Siegal S. Benign paroxysmal peritonitis. Ann Intern Med 1945; 23: 1–22.
4. Siegal S. Familial paroxysmal polyserositis: analysis of fifty cases. Am J Med 1964; 36: 893–918.
5. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17(1): 25–31.
6. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997; 90(4): 797–807.
7. Toplak N, Doležalová P, Constantin T et al. Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey. Pediatr Rheumatol Online J 2010; 8: 29.
8. Dallos T, Lukáčiková Gálová L, Macejková E et al. Familiárna stredomorská horúčka – prvé skúsenosti na Slovensku. Vnitř Lék 2014; XXX: 60(1): 80–85.
9. Buskila D, Zaks N, Neumann L et al. Quality of life of patients with familial Mediterranean fever. Clin Exp Rheumatol 1997; 15(4): 355–360.
10. Booth DR, Gillmore JD, Lachmann HJ et al. The genetic basis of autosomal dominant familial Mediterranean fever. QJM 2000; 93(4): 217–221.
11. Sood R, Blake T, Aksentijevich I et al. Construction of a 1-Mb restriction-mapped cosmid contig containing the candidate region for the familial Mediterranean fever locus (MEFV) on chromosome 16p13.3. Genomics 1997; 42(1): 83–95.
12. Chae JJ, Wood G, Masters SL et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA 2006; 103(26): 9982–9987.
13. Aksentijevich I, Torosyan Y, Samuels J et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. Am J Hum Genet 1999; 64(4): 949–962.
14. Sohar E, Gafni J, Pras M et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med1967; 43(2): 227–253.
15. Padeh S, Livneh A, Pras E et al. Familial Mediterranean fever in children presenting with attacks of fever alone. J Rheumatol 2010; 37(4): 865–869.
16. Padeh S, Livneh A, Pras E et al. Familial Mediterranean Fever in the first two years of life: a unique phenotype of disease in evolution. J Pediatr 2010; 156(6): 985–989.
17. Samli H, Içduygu FM, Ozgöz A et al. Surgery for acute abdomen and MEFV mutations in patients with FMF. Acta Reumatol Port 2009; 34(3): 520–524.
18. Brik R, Shinawi M, Kasinetz L et al. The musculoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum 2001; 44(6): 1416–1419.
19. Heller H, Gafni J, Michaeli D et al. The arthritis of familial Mediterranean fever (FMF). Arthritis Rheum 1966; 9(1): 1–17.
20. Kees S, Langevitz P, Zemer D et al. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM 1997; 90(10): 643–647.
21. Majeed HA, Quabazard Z, Hijazi Z et al. The cutaneous manifestations in children with familial Mediterranean fever (recurrent hereditary polyserositis). A six-year study. Q J Med 1990; 75(278): 607–616.
22. Senel K, Melikoglu MA, Baykal T et al. Protracted febrile myalgia syndrome in familial Mediterranean fever. Mod Rheumatol 2010; 20(4): 410–412.
23. Lachmann HJ, Sengül B, Yavuzşen TU et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006; 45(6): 746–750.
24. Akar S, Soyturk M, Onen F et al. The relations between attacks and menstrual periods and pregnancies of familial Mediterranean fever patients. Rheumatol Int 2006; 26(7): 676–679.
25. Lidar M, Yaqubov M, Zaks N et al. The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol 2006; 33(6): 1089–1092.
26. Gafni J, Ravid M, Sohar E. The role of amyloidosis in familial mediterranean fever. A population study. Isr J Med Sci 1968; 4(5): 995–999.
27. Livneh A, Langevitz P, Zemer D et al. The changing face of familial Mediterranean fever. Semin Arthritis Rheum 1996; 26(3): 612–627.
28. Gershoni-Baruch R, Brik R, Lidar M et al. Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation. J Rheumatol 2003; 30(2): 308–312.
29. Cazeneuve C, Sarkisian T, Pêcheux C et al. MEFV-Gene analysis in Armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. Am J Hum Genet 1999; 65(1): 88–97.
30. Cazeneuve C, Ajrapetyan H, Papin S et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet 2000; 67(5): 1136–1143.
31. Ozçakar ZB, Yalçınkaya F. Vascular comorbidities in familial Mediterranean fever. Rheumatol Int 2011; 31(10): 1275–1281.
32. Rozenbaum M, Rosner I. Severe outcome of juvenile idiopathic arthritis (JIA) associated with familial Mediterranean fever (FMF). Clin Exp Rheumatol 2004; 22(4 Suppl 34): 75–78.
33. Fidder HH, Chowers Y, Lidar M et al. Crohn disease in patients with familial Mediterranean fever. Medicine (Baltimore) 2002; 81(6): 411–416.
34. Livneh A, Langevitz P, Zemer D et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40(10): 1879–1885.
35. Yalçinkaya F, Ozen S, Ozçakar ZB et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 2009; 48(4): 395–398.
36. Kondi A, Hentgen V, Piram M et al. Validation of the new paediatric criteria for the diagnosis of familial Mediterranean fever: data from a mixed population of 100 children from the French reference centre for auto-inflammatory disorders. Rheumatology (Oxford) 2010; 49(11): 2200–2203.
37. Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 2001; 9(7): 473–483.
38. Marek-Yagel D, Berkun Y, Padeh S et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum 2009; 60(6): 1862–1866.
39. Caglayan AO, DemiryilmazF, Ozyazgan I et al. MEFV gene compound heterozygous mutations in familial Mediterranean fever phenotype: a retrospective clinical and molecular study. Nephrol Dial Transplant 2010; 25(8): 2520–2523.
40. Ozen S, Aktay N, Lainka E et al. Disease severity in children and adolescents with familial Mediterranean fever: a comparative study to explore environmental effects on a monogenic disease. Ann Rheum Dis 2009; 68(2): 246–248.
41. Ter Haar N, Lachmann H, Ozen S et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72(5): 678–685.
42. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972; 287(25): 1302.
43. Zemer D, Pras M, Sohar E et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314(16): 1001–1005.
44. Ozçakar ZB, Yalçinkaya F, Yüksel S et al. Possible effect of subclinical inflammation on daily life in familial Mediterranean fever. Clin Rheumatol 2006; 25(2): 149–152.
45. Tatsuta E, Sipe JD, Shirahama T et al. Colchicine inhibition of serum amyloid protein SAA and SAP synthesis in primary mouse liver cell cultures. Arthritis Rheum 1984; 27(3): 349–352.
46. Livneh A, Zemer D, Langevitz P et al. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 1994; 37(12): 1804–1811.
47. Ben-Chetrit E, Scherrmann JM, Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum 1996; 39(7): 1213–1217.
48. Savgan-Gürol E, Kasapçopur O, Hatemi S et al. Growth and IGF-1 levels of children with familial Mediterranean fever on colchicine treatment. Clin Exp Rheumatol 2001; 19: (5 Suppl 24): 72–75.
49. Ozçakar ZB, Kadioğlu G, Siklar Z et al. The effect of colchicine on physical growth in children with familial mediterranean fever. Eur J Pediatr 2010; 169(7): 825–828.
50. Rollot F, Pajot O, Chauvelot-Moachon L et al. Acute colchicine intoxication during clarithromycin administration. Ann Pharmacother 2004; 38(12): 2074–2077.
51. Meinzer U, Quartier P, Alexandra JF et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 2011; 41(2): 265–271.
52. Moser C, Pohl G, Haslinger I et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant 2009; 24(2): 676–678.
53. Vargová, V, Macejová Ž. Naše skúsenosti s liečbou anakinrou u pacientky s CINCA/NOMID syndrómom. Rheumatologia 2011; 25(3): 121–125.
54. Kovács L, Hlavatá A, Paulovičová E et al. Syndrómy periodických horúčok – PFAPA syndróm. Pediatr prax 2009; 10(3): 141–144.
55. Kovács L, Hlavatá A, Baldovič M et al. Elevated immunoglobulin D levels in children with PFAPA syndrome. Neuro Endocrinol Lett 2010; 31(6): 743–746.
56. Król P, Katra R, Doležalová P. Syndromy periodických horeček. Čes-slov Pediat 2009; 64(10): 480–487.
57. Szturz P, Adam Z, Sedivá A et al. Schnitzler syndrome: diagnostics and treatment. Klin Onkol 2011; 24(4): 271–277.
58. Kallinich T, Haffner D, Niehues T et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007; 119(2): 474–483.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2014 Issue 1
Most read in this issue
- Effect of alcohol consumption on cardiac electrophysiology
- Familiar Mediterranean fever in Czech Republic
- Familial Mediterranean Fever – clinical picture, diagnosis and treatment
- Familial Mediterranean Fever – First Experiences in Slovakia